Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma

BACKGROUND: Preclinical data suggest that vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)‐β signaling interact to stimulate angiogenesis and suppress antitumor immune responses. Thus, combined inhibition of both pathways may offer greater antitumor activity compared wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Harding, James J., Do, Richard K., Yaqubie, Amin, Cleverly, Ann, Zhao, Yumin, Gueorguieva, Ivelina, Lahn, Michael, Benhadji, Karim A., Kelley, Robin K., Abou‐Alfa, Ghassan K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085979/
https://www.ncbi.nlm.nih.gov/pubmed/33811482
http://dx.doi.org/10.1002/cam4.3880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085979/
https://www.ncbi.nlm.nih.gov/pubmed/33811482
http://dx.doi.org/10.1002/cam4.3880

Ejemplares similares